ArticleScientific reports2018
Fabrication and In Vitro Characterization of a Tissue Engineered PCL-PLLA Heart Valve.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 80 citations in OpenAlex.
- Antibacterial and antibiofilm activity of novel nanofibers bandage formulated withChinese herbal medicines · 2026Article
- Improved Surface Properties and Enhanced Cell Adhesion on Poly-ε-Caprolactone for Heart Valve Tissue Engineering Applications via HInternational journal of molecular sciences · 2026Article
- Bacterial adhesion and erythrocyte integrity on polycaprolactone nanowire surfaces.RSC advances · 2025Article
- Electrospinning PLLA/PCL Blend Fibre-Based Materials and Their Biomedical Application: A Mini Review.Polymers · 2025Review
- Hydrogels in Cardiac Surgery: Versatile Platforms for Tissue Repair, Adhesion Prevention, and Localized Therapeutics.Gels (Basel, Switzerland) · 2025Review
- Recent advancements in polymeric heart valves: From basic research to clinical trials.Materials today. Bio · 2024Review
- Assessment of degradability and endothelialization of modified poly L-lactic acid (PLLA) atrial septal defect (ASD) occluders over time in vivo.Journal of cardiothoracic surgery · 2023Article
- Strategies for Development of Synthetic Heart Valve Tissue Engineering Scaffolds.Progress in materials science · 2023Article
- Characterization of PLA/PCL/Nano-Hydroxyapatite (nHA) Biocomposites Prepared via Cold Isostatic Pressing.Polymers · 2023Article
- Review
- Investigating the Effect of PCL Concentrations on the Characterization of PLA Polymeric Blends for Biomaterial Applications.Materials (Basel, Switzerland) · 2022Article
- Anisotropicity and flexibility in trilayered microfibrous substrates promote heart valve leaflet tissue engineering.Biomedical materials (Bristol, England) · 2022Article
- Natural Polymers in Heart Valve Tissue Engineering: Strategies, Advances and Challenges.Biomedicines · 2022Review
- Biodegradable Poly-ε-Caprolactone Scaffolds with ECFCs and iMSCs for Tissue-Engineered Heart Valves.International journal of molecular sciences · 2022Article
- Regulation of photo triggered cytotoxicity in electrospun nanomaterials: role of photosensitizer binding mode and polymer identity.Nanoscale advances · 2021Article
- Poly (ε-caprolactone)-based electrospun nano-featured substrate for tissue engineering applications: a review.Progress in biomaterials · 2021Review
- A Review on Current Trends of Polymers in Orthodontics: BPA-Free and Smart Materials.Polymers · 2021Review
- Article
- Recapitulating Cardiac Structure and Function In Vitro from Simple to Complex Engineering.Micromachines · 2021Review
- Sustainable drug release from polycaprolactone coated chitin-lignin gel fibrous scaffolds.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart valve diseases are among the leading causes of cardiac failure around the globe. Nearly 90,000 heart valve replacements occur in the USA annually. Currently, available options for heart valve replacement include bioprosthetic and mechanical valves, both of which have severe limitations. Bioprosthetic valves can last for only 10-20 years while patients with mechanical valves always require blood-thinning medications throughout the remainder of the patient's life. Tissue engineering has emerged as a promising solution for the development of a viable, biocompatible and durable heart valve; however, a human implantable tissue engineered heart valve is yet to be achieved. In this study, a tri-leaflet heart valve structure is developed using electrospun polycaprolactone (PCL) and poly L-lactic acid (PLLA) scaffolds, and a set of in vitro testing protocol has been developed for routine manufacturing of tissue engineered heart valves. Stress-strain curves were obtained for mechanical characterization of different valves. The performances of the developed valves were hemodynamically tested using a pulse duplicator, and an echocardiography machine. Results confirmed the superiority of the PCL-PLLA heart valve compared to pure PCL or pure PLLA. The developed in vitro test protocol involving pulse duplicator and echocardiography tests have enormous potential for routine application in tissue engineering of heart valves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.